Chris Mauney Vice President

Chris Mauney, Vice President at NovaQuest Capital Management, has experience advancing a range of drug development and regulatory programs across diverse indications and therapeutic modalities. He is responsible for due diligence, structuring of investment opportunities, and post-close investment management.

Prior to joining NovaQuest, Dr. Mauney was a scientific and regulatory consultant with Syneos Health, a global contract research organization, with a focus on nonclinical development strategy. His earlier experiences include integrated product development with the mid-size contract research organization Rho; biomedical product development to address global public health challenges as a technical analyst with USAID; and postdoctoral training in biochemistry and biophysics.

Dr. Mauney earned a BA in English from Wake Forest University, a MS in Biotechnology from Johns Hopkins, MBA from Wake Forest University, and a PhD in Biochemistry and Molecular Biology from Wake Forest University.

The information being provided is strictly as a courtesy. When you link to any of the websites provided here, you are leaving this website. We make no representation as to the completeness or accuracy of information provided at these websites, nor do we assume any risk of using such websites.

Proceed to Link